Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
Receive an email update when we add a new DUCHENNE MUSCULAR DYSTROPHY article.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- US Duchenne Muscular Dystrophy Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, And ... on October 5, 2018 at 9:10 am
DUBLIN--(BUSINESS WIRE)--The "US Duchenne Muscular Dystrophy Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Duchenne Muscular Dystrophy Market ... […]
- Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More on October 5, 2018 at 6:50 am
In other news this week, encouraging early data emerged for a gene therapy for Duchenne muscular dystrophy, a company snagged two FDA approvals in one day, and the fourth quarter kicked off with one o... […]
- Gene editing and muscular dystrophy on October 4, 2018 at 1:29 pm
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weakness and a shortened life span. The disease is caused by mutations that reduce or prevent expression of dystrophin, an esse... […]
- CureDuchenne Partners with Baebies to Accelerate Newborn Screening for Duchenne Muscular Dystrophy on October 4, 2018 at 6:21 am
CureDuchenne, the nation’s leading nonprofit funding scientific research and innovation for Duchenne muscular dystrophy, announced today it has entered into a three-year partnership with Baebies. A gr... […]
- Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy on October 4, 2018 at 3:56 am
For the first time, a gene therapy—a one-time, long-lasting treatment—has shown it may improve the lives of kids with Duchenne muscular dystrophy, a deadly genetic disease with no cure. Patients in a ... […]
- Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy on October 3, 2018 at 2:30 pm
An experimental gene therapy dramatically improved the ability of a young boy with Duchenne muscular dystrophy to rise from the ground or climb stairs, repeating and improving on results seen in three ... […]
- Hop, skip, jump. Sarepta’s Duchenne gene therapy delivers early muscle function improvements on October 3, 2018 at 2:21 pm
In a clinical trial earlier this year, an experimental gene therapy for Duchenne muscular dystrophy, licensed to Sarepta Therapeutics (SRPT), produced large increases in a crucial muscle protein norma... […]
- Duchenne Muscular Dystrophy Market Is Driven by the Rising Demand for Effective Therapies Among Patients on October 3, 2018 at 10:14 am
Albany, NY -- (SBWIRE) -- 10/03/2018 -- Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) cause due to lack o... […]
- Promising new therapy spares muscle loss in Duchenne muscular dystrophy on October 1, 2018 at 1:30 pm
A promising therapy for Duchenne muscular dystrophy (DMD) developed by UB researchers is moving closer to use in humans. New research, published in July in Neuromuscular Disorders, demonstrates the no... […]
via Bing News